# Nuclide record dlbcl (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/dlbcl/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "dlbcl" ;
  schema:name "Diffuse large B-cell lymphoma"@en ;
  schema:description "Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."@en ;
  schema:url <https://nuclide.cc/indications/dlbcl/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q2626074> ;
  schema:citation <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma> ;
  nuclide:tag "heme", "spike" ;
  nuclide:related <https://nuclide.cc/indications/follicular-lymphoma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/fdg-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/cd20/> ;
  nuclide:companies <https://nuclide.cc/companies/bms/>, <https://nuclide.cc/companies/merck/>, <https://nuclide.cc/companies/novartis/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mskcc/>, <https://nuclide.cc/institutions/md-anderson/>, <https://nuclide.cc/institutions/dana-farber/>, <https://nuclide.cc/institutions/mayo-clinic/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/fdg-pet/> .